PDP Pediapharm

Pediapharm Inc. ("Pediapharm" or the "Corporation") (TSX VENTURE:PDP) is pleased
to announce that it has engaged Paradox Public Relations Inc. ("Paradox") as
strategic investor relations consultants to the Corporation. Paradox will focus
on developing and expanding Pediapharm's communications with the investment
community through a comprehensive investor relations program.


Paradox is an investor relations company founded in 2001 and is based in
Montreal, Canada. Paradox provides a wide range of services to companies to help
broaden investor exposure and develop a shareholder following. 


The term of the agreement entered into between the Corporation and Paradox is
for an initial period of six months. In consideration for its services,
Pediapharm has agreed to pay to Paradox a monthly fee of $6,800. In addition,
the Corporation has granted to Paradox stock options giving it the right to
purchase up to 100,000 common shares of the Corporation at an exercise price of
$0.36 per common share for a period of one year. The options granted will vest
monthly in 12 equal tranches starting on the grant date. 


About Pedipharm Inc. 

Pediapharm is the only Canadian specialty pharmaceutical company dedicated to
serving the needs of the pediatric community. Its mission is to bring to the
Canadian market the latest innovative pediatric products with the objective to
improve the health and the well-being of children in Canada. Since its debut in
2008, Pediapharm has entered into numerous commercial agreements with partners
from Canada and other countries around the world. The company's innovative
product portfolio includes NYDA(R); a breakthrough treatment for head lice;
EpiCeram(R) a non-steroid emulsion for eczema; KoolEffect(TM) which reduces the
symptoms of fever; and VapoLyptus(TM); a soothing vapour patch of Eucalyptus and
Camphor. 


About Paradox Public Relations Inc. 

Paradox Public Relations Inc. was formed in 2001 and is headquartered in
Montreal, Quebec, Canada. Its bilingual (English and French) team of
professionals offers experience and expertise in investor relations, corporate
communications and non-deal road shows. Paradox specializes in the development
and marketing of emerging growth, micro cap and small cap companies. With over
13 years of continued service, Paradox has developed extensive national and
international contacts including brokers, investment advisors, institutional
investors, investment funds, analysts, newsletter writers, media and private
investors. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Pediapharm Inc.
Sylvain Chretien
President and Chief Executive Officer
+1-514-762-2626 ext. 201
sylvain.chretien@pedia-pharm.com


Roland Boivin
Chief Financial Officer
+1-514-762-2626 ext. 202
roland.boivin@pedia-pharm.com


Relations Publiques Paradox Public Relations Inc.
Carl Desjardins
+1-514-341-0408
carldesjardins@paradox-pr.ca

Pediapharm Inc. (TSXV:PDP)
Historical Stock Chart
Von Mai 2024 bis Jun 2024

Pediapharm Inc. (TSXV:PDP)
Historical Stock Chart
Von Jun 2023 bis Jun 2024